Role of NF-κB in Thyroid Cancer

Thyroid Cancer: From Emergent Biotechnologies to Clinical Practice Guidelines

Volumn , Issue , 2016, Pages 319-327

  Suzuki, Eriko ^a   Yamashita, Shunichi ^b   Umezawa, Kazuo ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873197293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b10945-24     Document Type: Chapter

References (38)

1. Nikiforov YE. 2006. Radiation-induced thyroid cancer: What we have learned from chernobyl. Endocr Pathol 17:307-17.
2. Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M, Imai K, Cologne J, Soda M, Arihiro K, Fujihara M, Abe K, Hayashi T, Nakashima M, Sekine I, Yasui W, Hayashi Y, Nakachi K. 2008. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 68:7176-82.
3. Xing M. 2007. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-62.
4. Sen R, Baltimore D. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705-16.
5. Israel A, Le Bail O, Hatat D, et al. 1989. TNF stimulates expression of mouse MHC class I genes by inducing an NF-κB-like enhancer binding activity which displaces constitutive factors. EMBO J 8:3793-800.
6. Baldwin AS Jr. 1996. The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol 14:649-83.
7. Tanaka S, Nakamura K, Takahasi N, Suda T. 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208:30-49.
8. Fagerlund R, Melén K, Cao X, Julkunen I. 2008. NF-kappaB p52, RelB and c-Rel are transported into the nucleus via a subset of importin alpha molecules. Cell Signal 20:1442-51.
9. Debatin KM. 2004. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53:153-59.
10. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. 2001. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families. Histol Histopathol 16:595-601.
11. Rayet B, Gélinas C. 1999. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-47.
12. Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P, Yan G. 2009. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappaB pathway. Mol Pharmacol 75:812-19.
13. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67.
14. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. 1996. Suppression of TNF-a-induced apoptosis by NF-κB. Science 274:787-89.
15. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA. 2000. PAX8-PPAR 1 fusion oncogene in human thyroid carcinoma. Science 289:1357-60.
16. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY. 2006. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kB signaling pathway. Oncogene 25:2736-47.
17. Namba H, Saenko V, Yamashita S. 2007. Nuclear factor kB in thyroid carcinogenesis and progression: A novel therapeutic target for advanced thyroid cancer. Arq Bras Endocrinol Metab 51:843-51.
18. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S, Inoue J, Umezawa K. 2000. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 10:865-69.
19. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. 2002. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 277:24625-30.
20. Suzuki Y, Sugiyama C, Ohno O, Umezawa K. 2004. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron 60:7061-66.
21. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K. 2008. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 51:5780-88.
22. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. 2005. Targeting of nuclear factor kappaB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11:1287-93.
23. Tamano S, Ward JM, Diwan BA, Keefer LK, Weghorst CM, Calvert RJ, Henneman JR, Ramljak D, Rice JM. 1996. Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats. Carcinogenesis 17:2477-86.
24. Suzuki E, Umezawa K. 2006. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother 60:578-86.
25. Wang L, Chen W, Xie X, He Y, Bai X. 2008. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp Oncol 30:42-51.
26. Han YP, Tuan TL, Wu H, Hughes M, Garner WL. 2001. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 114:131-39.
27. Sakurai T, Maeda S, Chang L, Karin M. 2006. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103:10544-51.
28. Cusack JC Jr, Liu R, Xia L, Chao TH, Pien C, Niu W, Palombella VJ, Neuteboom ST, Palladino MA. 2006. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 12:6758-64.
29. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S. 2004. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, DHMEQ. Clin Cancer Res 10:6821-29.
30. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S. 2006. BRAFV600E promotes invasiveness of thyroid cancer cells through NF-κB activation. Endocrinology 147:5699-707.
31. Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A, Yamashita S. 2008. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 149:5357-65.
32. Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S. 2004. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 89:410-18.
33. Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, Yamamoto N, Umezawa K, Horie R. 2005. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 114:32-38.
34. Ohsugi T, Kumasaka T, Okada S, Ishida T, Yamaguchi K, Horie R, Watanabe T, Umezawa K. 2007. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. Cancer Lett 257:206-15.
35. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M. 2003. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 63:107-10.
36. Umezawa K. 2006. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci 97:990-95.
37. Festa M, Petrella A, Alfano S, Parente L. 2009. R-Roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. Int J Cancer 124:2728-36.
38. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M, De Maria R. 2007. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 92:1938-42.